A Novel miR-129 Mimic as a Therapeutic for Colon Cancer

Background

In the last 15 years, it has become well established that microRNAs play important roles in cancer biology. Due to their ability to regulate the expression of important target genes, aberrant expression of miRNAs has been linked to cancer development and progression. Based on these important functions, there is great interest in developing miRNA based therapeutics. One miRNA, miR-129, has been shown to have important roles in colon cancer.

Technology

In the interest of developing miR-129 based cancer therapeutics, researchers at Stony Brook University have made a modified miR-129 mimic that shows enhanced abilities to disrupt resistant cancer cell proliferation and induction of cell cycle arrest when compared to unmodified miR-129. This miR-129 mimic also maintains its ability to regulate important miR-129 target genes in cancer stem cells. In mouse models using cancer stem cells, miR-129 mimic has demonstrated therapeutic potential by reducing tumor growth. Based on these findings, there is potential that modified miR-129 modified miR-129 may be a novel therapeutic to improve survival of advanced stage colon cancer patients.

Advantages

More potent, less toxic and higher specificity than current therapeutic agent.

Application

Cancer therapeutics

Patent Status

Patent application submitted

Stage Of Development

In-vitro and in-vivo data. Provisional filed

Licensing Potential

Licensing

Licensing Status

Available for License

Additional Info

https://stonybrook.technologypublisher.com/files/sites/8859-novel-mir129-based-cancer-therapeutics.jpg Please note, header image is purely illustrative. Source: Patho, Wikimedia Commons, CC BY-SA 3.0

Category(s):

Drug Design and/or Synthesis

Therapeutics

Campus > Stony Brook University

Case ID: R8859

Bookmark this page

Download as PDF

For Information, Contact:

Valery Matthys

Licensing Associate

State University of New York at Stony Brook

valery.matthys@stonybrook.edu

Inventors:

Jingfang Ju